New generation antidepressants for depression in children and adolescents: a network meta-analysis (Protocol)

Sarah E. Hetrick, Nicholas Meader, Alan P. Bailey, Paul B. Badcock, Carl I. Moller, Georgina R. Cox, Sally N. Merry, Joanne E. McKenzie

Research output: Contribution to journalArticleResearchpeer-review

Abstract

Objectives: This is a protocol for a Cochrane Review (intervention). The objectives are as follows:. To investigate, via network meta-analyses (NMA), the comparative effectiveness and safety of different newer generation antidepressants in children and adolescents with a diagnosed major depressive disorder (MDD). Specific objectives, in order of priority, are to:. estimate the relative effects of newer generation antidepressants compared with placebo and with each other on depression, functioning, suicide-related outcomes and other adverse outcomes; estimate the relative ranking of the included newer generation antidepressants for the outcomes of depression, functioning, suicide-related outcomes and other adverse outcomes; and, examine whether the relative effects on clinician-rated depression symptoms and suicide-related outcomes estimated in objectives 1 and 2 are modified by age, treatment duration, baseline severity and pharmaceutical industry funding of the antidepressant under evaluation.

Original languageEnglish
Article numberCD013674
Number of pages22
JournalCochrane Database of Systematic Reviews
Volume2020
Issue number7
DOIs
Publication statusPublished - 9 Jul 2020

Cite this